Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Lifeline Scientific (LSI)

  Print      Mail a friend

Thursday 18 June, 2009

Lifeline Scientific

Research Update

RNS Number : 0966U
Lifeline Scientific, Inc
18 June 2009

18 June 2009

Lifeline Scientific, Inc('Lifeline' or 'the Company')Trial Results Published at American Transplant Congress

Data from non-heart beating donors and donors over 65 further underline clear advantages of machine perfusion over traditional ice box storage for kidney transplants 

Study demonstrates long-term cost effectiveness of machine perfusion versus static cold storage 

Lifeline Scientific, the medical technology company focused on commercialising its LifePort® Kidney  Transporter,  announces the presentation of further data supporting the advantages of it's machine perfusion device over the standard practice of static storage using ice in a cool box.  The data was presented last week at the American Transplant Congress in BostonUS.

The results demonstrate that kidneys from non-heart beating donors (NHBD) and from donors older than 65 years have a reduced risk of delayed graft function when preserved with the LifePort than kidneys stored in a cool box. Non-heart beating and older donors represent a significant potential new resource to help solve the global shortage of donor organs for transplant.  A transplant patient who receives a kidney that does not work immediately will need to receive post-transplant dialysis treatment.  In older donor kidneys, the risk of primary non function is four time less likely in kidneys that are LifePorted as compared to the box of ice.  

Another study demonstrated the long term cost-effectiveness of LifePort machine perfusion compared with static cold storage in kidney transportation.

Highlights of the Results


·      Machine perfusion of non-heart beating donor kidneys reduces incidence, duration and severity of delayed graft function after kidney transplantation.
·       Kidneys of donors older than 65 years show a clear advantage when preserved in the LifePort, especially in case of delayed graft function.
·       Cost-effectiveness and cost-utility ratios suggest that life years and quality adjusted life years can be gained while  reducing cost at the same time.


In January of this year, landmark trial results published in the New England Journal of Medicine showed that for transplanted kidneys preserved and transported in Lifeline's LifePort Kidney Transporter, the odds of experiencing a delay in recovery of kidney function are 43% lower, and that these kidneys are 48% less likely to fail within a year compared to those stored in the traditional box of ice.

David Kravitz, Chief Executive of Lifeline Scientific, said:'These results are yet further evidence of the clear advantages of LifePort machine perfusion over traditional static ice box storage. The mounting body of evidence in support of the clinical benefits and cost-effectiveness of our machine perfusion technology over traditional cold storage methods underlines the potential for LifePort to be an important new tool for transplant medicine. We look forward to accelerating the full commercial rollout of LifePort this year.'  



Lifeline Scientific, Inc.

David Kravitz, CEO

Seymour Pierce (Nomad)

+44 (0)20 7107 8000

Mark Percy / Huaizheng Peng / Sarah Jacobs

Financial Dynamics

+44 (0)20 7831 3113

Ben Brewerton / John Dineen



Detailed Results

1. Machine perfusion versus cold storage preservation in non-heart-beating kidney donation and transplantation

This analysis of the Machine Preservation Trial compared outcomes in 82 pairs of kidney from non heart-beating-donors, which were assigned to either machine preservation (MP) with the LifePort or to conventional cold storage (CS). All 164 recipients were followed up at three months post transplantation. Statistically significant results showed that delayed graft function (DGF) was strongly reduced. (Duration of DGF [days] was 9 in MP vs. 13 in CS, p=0.05. DGF < 7 days occurred in 27% in the MP vs. 10.5% in the CS arm, p=0.028).

2. Machine perfusion versus cold storage in transplantation of kidneys from older deceased donors: results of a prospective randomized multicentre trial

A second analysis compared 118 pairs of kidneys from donors 55 years old and older which were randomly assigned to either machine preservation or cold storage. All 236 recipients were followed up at 6 months.  Although this trial utilised expanded criteria organs and DGF did occur in both MP and CS group ( with the incidence of DGF 22% in MP vs. 31.4 % in CS recipients, p=0.07), the trial demonstrated that the function of MP kidneys recovered faster that those in the CS group (DGF <7 days occurred in 10 recipients in the MP vs. 5 in the CS arm, p=0.02). When DGF occurred six month graft survival was significantly better in kidneys preserved with MP than by CS: 84% vs. 60%, p=0.026.

In addition this trial demonstrated statistically significant results in favour of MP in respect of primary non function (2.5% in MP vs. 10.2% in CS kidney recipients, p=0.015). 


About the Machine Preservation Trial

The Machine Preservation Trial is the first prospective, statistically powered, randomized, controlled, multicentre trial to investigate the efficacy, cost effectiveness and practicalities of continuous hypothermic machine perfusion from donor to recipient versus static storage in deceased donor kidneys. The trial lasted for two years.

The Machine Preservation Trial was conducted in collaboration with Eurotransplant and the Deutsche Stiftung Organtransplantation ('DSO'). Since 1 November 2005, all cadaveric kidney donors over 16 years of age from Belgium, The Netherlands, and the DSO Region Nordrhein-Westfalen Germany were considered for enrollment in the trial. The trial was sponsored by Organ Recovery Systems, an operating business of Lifeline Scientific.

The trial compared outcomes in 336 pairs of kidneys, one preserved with machine preservation on the LifePort and the other by static ice box storage.

About the LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is designed to provide improved kidney preservation, evaluation and transport prior to transplantation. LifePort provides a sealed, sterile, protected environment where a solution is gently pumped through the kidney at cold temperatures to minimize damage while the organ is outside the body. LifePort is lightweight and portable, allowing organs to be perfused from the time of recovery until transplant. It is designed to travel unaccompanied by land or air, safely transporting the kidneys across town or between countries. While the kidney is being perfused, the LifePort records data on temperature, flow rate, vascular resistance and pressure every 10 seconds providing surgeons with additional data prior to transplant. During its pilot introduction, over 300 LifePorts have been installed in 90 transplant programmes worldwide treating more than 17,000 kidneys for clinical transplant.  

About Lifeline Scientific Inc.  

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with European headquarters located in Brussels. Its primary focus is to commercialise its FDA approved, CE marked, clinically validated and revenue generating LifePort Kidney Transporter. Devices for preservation of the heart, lung, pancreas and liver are in late stage pre-clinical development.

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t